| Document |
Document Title |
|
WO/1993/020182A1 |
Micro-organisms capable of selectively producing streptogramine components A and B, the preparation of said micro-organisms, the resulting streptogramines, and uses thereof, are disclosed.
|
|
WO/1993/012659A1 |
Use of compounds of general formula (I), wherein R1 and R2 are methyl or hydrogen, R3 is: cyclohexyl, cyclohexenyl, or phenyl substituted in the para position, R4 is hydrogen, carboxy alkoxycarbonyl, optionally mono- or plurisubstituted,...
|
|
WO/1993/001828A1 |
Compounds wherein therapeutic peptides, including HIV protease inhibitors, are covalently linked to phospholipids, glycerides or other membrane-targeting and membrane-anchoring species, and their pharmaceutically acceptable salts, togeth...
|
|
WO/1993/000362A1 |
Described are peptides of formula (I), in which R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, X?1¿ and X?2¿ are as defined in the description, as well as their preparation. The new peptides are suitable for use in the treatment of illnesses.
|
|
WO/1992/007870A1 |
A platelet aggregation inhibitor useful as an antithrombotic is provided which consists of a synthetic cyclic pentapeptide containing the tripeptide sequence Lys-Gly-Asp and a thioether linkage in the cycle. A prefered platelet aggregati...
|
|
WO/1992/005191A1 |
Novel compounds of the general composition I, Lactate (1), Glycine (1), Valine (4), Isoleucine (1), pipecolic acid (1), Aspartic acid (1), Tyrosine (1), wherein each amino acid residue independently may occur in L- or D- form, and wherei...
|
|
WO/1992/004374A1 |
A novel polypeptide having an antiviral activity against human immunodeficiency virus (HIV), represented by the above formula (I), a pharmaceutically acceptable salt thereof, and an anti-HIV drug containing the same as the active ingredi...
|
|
WO/1991/009052A1 |
The invention relates to novel peptide derivatives with the formula: R1-A1-A2-A3-A4-R2 or its salt, wherein R1 = H or a protective group; A1 = H, Ile, Leu or Val; A2 = Glu, Asp, Ser, Thr; A3 = Gly or Glyc; A4 = Arg or Lys; R2 = 4-nitro a...
|
|
WO/1991/004985A1 |
Dehydrodidemnin B with useful biological activity is of formula (I). It can be isolated from natural sources or synthesised, and forms active derivatives.
|
|
WO/1980/002157A1 |
A peptide having the formula A-B wherein A represents an N-terminal protected amino acid residue or an optionally N-terminal protected peptide residue and B represents an optionally C-terminal protected amino acid residue, is prepared by...
|
|
JP2024045244A |
[Problem] It has the ability to bind to BIG3, a protein that is highly expressed specifically in estrogen receptor-positive cancers, and has an excellent growth-inhibiting effect on BIG3-positive cancer cells. Provided are peptides and p...
|
|
JP2024045275A |
Peptides capable of inhibiting muscarinic receptor M3 activity and products containing such peptides, particularly skin conditions mediated by muscarinic receptor M3 activity, such as excessive sweating, inflammation, sebum production, a...
|
|
JP2024023191A |
The present invention provides an antibody-drug conjugate (ADC) that exhibits much superior antitumor antibiotic activity in clinical applications. The present invention relates to novel cross-linked cytotoxic agents, pyrrolobenzodiazepi...
|
|
JP2024506919A |
The present application, which is an artificial small-molecule interfering peptide of DAPK1 phosphorylation substrate and its pharmaceutical use, relates to the field of small-molecule polypeptide drug development, and the provided small...
|
|
JP2024009021A |
An object of the present invention is to provide an improved synthetic route to emodepside and related cyclic depsipeptides. The present invention relates to a method for synthesizing cyclic depsipeptides, particularly emodepside, from a...
|
|
JP2023175683A |
To provide bicyclic peptide ligands specific for Eph receptor tyrosine kinase A2 (EphA2).The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are sub...
|
|
JP2023166457A |
To provide amino acids, peptides, and polypeptide-lipids that are effective as a drug delivery system including the delivery of nucleotides to cells.The present invention discloses compounds prepared by reacting terminal or internal amin...
|
|
JP7378839B2 |
The present invention relates to acetylcholine receptor inhibitory peptides and uses thereof, wherein phages with high binding affinity for acetylcholine receptors were screened using a random peptide recombinant phage, and acetylcholine...
|
|
JP7377242B2 |
The present invention provides a novel macrocyclic prodrug compound of general Formula (I), a pharmaceutical composition comprising a compound of Formula (I), and a method for treating diseases mediated by HDAC enzymes by administering a...
|
|
JP2023153947A |
To provide anti-fungal compounds and methods of treating plants to control plant diseases.The present invention relates to a composition comprising a biologically pure culture of a fungicidal strain of Paenibacillus sp. having a variant ...
|
|
JP2023139183A |
To provide a compound, a pharmaceutical composition, and a method for treating diseases mediated by HDAC enzymes.The present invention provides a novel macrocyclic prodrug compound of the formula (I).SELECTED DRAWING: None
|
|
JP2023129587A |
To provide structurally-stabilized and/or cysteine-reactive NOXA peptides.This disclosure relates to structurally-stabilized and/or cysteine-reactive NOXA BH3 peptides that can covalently bind to BFL-1 and also bind to BFL-1 and/or MCL-1...
|
|
JP2023537111A |
The present invention provides a cyclic chemerin-9 derivative of general formula (I) as described and defined herein, a method for preparing said peptide and a method for the treatment or prevention of diseases, in particular cancer, dia...
|
|
JP2023536746A |
The disclosure provides peptides, peptide compositions, immunotherapeutic compositions, pharmaceutical compositions and nucleic acids comprising one or more tau peptides. The disclosure also provides methods of treating or effecting the ...
|
|
JP2023100903A |
To provide methods for altering the distribution of a cell surface antigen.The methods include: bringing a cell into contact with a plurality of meditope enabled antibodies or antigen binding fragments thereof capable of binding to a cel...
|
|
JP2023100821A |
To provide a composition for preventing or treating arteriosclerosis.The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising an LGI 3 antagonist represented by a specific amino ...
|
|
JP2023530128A |
The present invention relates to conjugates of camptothecin analogues represented by formula (I) and cell-binding molecules, wherein R1, R2, R3, R4, R5, X, L, n, m, T, and [Chemical 1] is defined herein. Also provided are methods of maki...
|
|
JP7269398B2 |
A thioester compound of Formula (XXV) is described:or a pharmaceutically acceptable salt thereof, wherein X, Y, Z, R1-R14are defined herein. The compounds are useful in medicine, for example for use in the treatment of a disorder mediate...
|
|
JP2023517535A |
The present invention relates to the use of compounds in the treatment of viral infections, wherein said virus is selected from the Orthomyxoviridae family or said virus is West Nile virus.
|
|
JP2023517537A |
The present invention relates to the use of compounds in the treatment of autoimmune conditions, particularly rheumatoid arthritis.
|
|
JP2023517536A |
The present invention relates to the use of compounds in the treatment of inflammation, preferably inflammation associated with activation of Toll-like receptors. The invention also relates to the use of the compounds to treat pathogen-i...
|
|
JP2023517295A |
Formula (I) for use in treating coronavirus infection [Chemical 1] compound. (Wherein, X, Y, n, p, q, and R1~R17has various meanings)
|
|
JP2023030213A |
To provide novel depsipeptides and uses thereof.The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptide...
|
|
JP2023021170A |
To provide methods for synthesizing a peptide containing amino acids with various structures, which can achieve superior translation efficiency compared to the conventional method that does not use ARAS and prepares aminoacyl-tRNA having...
|
|
JP7206222B2 |
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
|
|
JP7201181B2 |
An object of the present invention is to provide an echinomycin derivative that has anti-cancer activity equal to or greater than that of echinomycin, and a production method therefor based on a chemical procedure. Provided are an echino...
|
|
JP7194115B2 |
The present invention relates generally to novel depsipeptides, to methods for the preparation of the novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides...
|
|
JP2022548100A |
The subject matter of the present invention exhibits high catalytic activity at difficult reaction conditions, especially high concentrations of salts and other additives commonly used in protein and virus purification processes, low tem...
|
|
JP7112753B2 |
The invention provides Dsg2-derived peptides for inhibiting EMT and/or vasculogenic mimicry and treating and/or preventing angiogenesis-related diseases. Also provided are pharmaceutical compositions comprising the peptide of the inventi...
|
|
JP2022096646A |
To provide adhesive polypeptides with excellent adhesion and biocompatibility to biological tissues and inorganic materials.Provided is an adhesive polypeptide that has a total of 1 to 100 polypeptide chains (y1) and/or polypeptide chain...
|
|
JP2022058411A |
To provide a reagent and a method for detecting a target analysis object in a complicated biological sample, with high sensitivity, quantitatively and simultaneously, by a liquid chromatography tandem mass analysis (LC MS/MS), in some as...
|
|
JP2022058535A |
To provide cyclic depsipeptide compounds that are effective against parasites that harm animals, and compositions comprising the compounds.The compounds and compositions may be used for combating parasites in or on mammals and birds. The...
|
|
JP7045191B2 |
The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasi...
|
|
JP7033677B2 |
A thioester compound of Formula (XXV) is described:or a pharmaceutically acceptable salt thereof, wherein X, Y, Z, R1-R14are defined herein. The compounds are useful in medicine, for example for use in the treatment of a disorder mediate...
|
|
JP2022510770A |
To provide an antibacterial peptide and a method for using the same. Aspects of the present invention relate to peptides having antibacterial activity. In one aspect, the invention relates to peptides having strong antibacterial activity...
|
|
JP6983808B2 |
Provided are self-crosslinking meditope-enabled antibodies. Also provided are methods for altering the distribution of a cell surface antigen using self-crosslinking meditope enabled antibodies, compositions for use in the methods, and m...
|
|
JPWO2020130125A1 |
An antibody-drug conjugate in which a drug linker and an antibody bound by a thioether bond represented by the following formula (A indicates a binding position with an antibody) and a kinase inhibitor (CDK4 / 6 inhibitor, mTOR inhibitor...
|
|
JP6943859B2 |
The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals, including humans. The compounds and compositions may be used fo...
|
|
JP2021522172A |
Compositions and uses, such as pharmaceutical compositions for peptide-drug complexes, are disclosed. Such compositions may deliver drugs, peptides, or complexes thereof to target areas, tissues, structures or cells in cartilage. In vari...
|
|
JPWO2020066343A1 |
An object of the present invention is to provide a novel cell membrane penetrating peptide having excellent cell membrane permeability. The cell membrane penetrating peptide or salt thereof according to the present invention is character...
|
